Neutral
aTyr Pharma reported a net loss of $10.8 million for Q1 2026, an improvement from $14.9 million in Q1 2025. The company plans to submit an Investigati...
Bullish
aTyr Pharma reported Q1 2026 results, ending March 31, 2026, with $68.3 million in cash. The company plans to file an IND in June 2026 for a new globa...
Neutral
aTyr Pharma (NASDAQ: ATYR) announced its first quarter 2026 results and provided a corporate update, including a clear path forward for efzofitimod in...